Catalog No.
DHC15805
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Hybridoma growth factor, BSF-2, IFN-beta-2, CDF, IL6, Interleukin-6, IL-6, B-cell stimulatory factor 2, Interferon beta-2, IFNB2, CTL differentiation factor
Concentration
1.55 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05231
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ALD-518, BMS-945429, CAS: 1236278-28-6
Clone ID
Clazakizumab
[IL-6 blockade], PMID: 27311186
A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection, PMID: 33443079
A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis, PMID: 28926467
Anti-cytokines in the treatment of cancer cachexia, PMID: 30180740
Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism, PMID: 34153143
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial, PMID: 30635033
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis, PMID: 31272807
Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis, PMID: 29244162
Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review, PMID: 30328022
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, PMID: 28264816
From mechanism to therapies in systemic lupus erythematosus, PMID: 28118202
IL-6 Directed Therapy in Transplantation, PMID: 34099967
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future, PMID: 25648633
Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients, PMID: 33688459
Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities, PMID: 28707587
Interleukin-6 blocking agents for treating COVID-19: a living systematic review, PMID: 33734435
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond, PMID: 31523783
New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment, PMID: 33315763
Outpatient management of kidney transplant recipients with suspected COVID-19-Single-center experience during the New York City surge, PMID: 32578324
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis, PMID: 32381564
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis, PMID: 28579757
Proposal for a new nomenclature of disease-modifying antirheumatic drugs, PMID: 24072562
Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology, PMID: 29185959
Rheumatoid arthritis: new monoclonal antibodies, PMID: 29771256
Role of monoclonal antibody drugs in the treatment of COVID-19, PMID: 33083387
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial, PMID: 33115543
Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report, PMID: 32563584
Targeting interleukin-6 for noninfectious uveitis, PMID: 26392750
The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis, PMID: 27059799
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study, PMID: 26138593
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer, PMID: 30372844
For research use only. Not for human or drug use.
